One of the major challenges of measurable residual disease (MRD) utilization is the standardization of its measurement and reporting. Here, Christopher Hourigan, MD, DPhil, of the National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, discusses how we could move towards the harmization of MRD monitoring in acute myeloid leukemia (AML) and emphasizes the benefits that this could have. This video was recorded at the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden.
